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1. Introduction 
The most common form of dementia is Alzheimer’s disease (AD) (Blennow et al., 2006). Due 
to worldwide demographic aging, its incidence and socioeconomic impact is going to be 
growing noticeably within the next fifty years (Sloane et al., 2002). Typically the disease 
progresses slowly with a mean decline of about 3 MMSE (Mini Mental Status Examination) 
pts/yr (Morris et al., 1993). On average, patients survive 8 years after the diagnosis has been 
established (Goldberg, 2007). But sometimes fast progressive AD forms with distinct clinical 
features are observed (Caselli et al., 1998; Josephs et al., 2009; Mann et al., 1989; Schmidt et 
al., 2010; van Everbroeck et al., 2004). 
During the past few years AD has increasingly being understood as a disease that appears 
in rather heterogeneous variants (Blennow et al., 2006; Wilkosz et al., 2010; van der Vlies et 
al., 2009a; Iqbal et al., 2005; Querfurth & LaFerla, 2010). This accounts for its clinical profile, 
biomarker patterns or neuropathological features. Still, studies sufficiently interrelating 
symptomatology to neuropathology, pathophysiology and biopathochemistry are lacking. 
Factors, which might cause heterogeneity, appear to be diverse. For instance, different 
deterioration speeds may occur in different disease stages (Wilkosz et al., 2010; Brooks et al., 
1993; Storandt et al., 2002). Also differences in the so-called cognitive reserve (Stern, 2006; 
Mortimer et al., 2005; Paradise et al., 2009) could account for phenotypical disparities. But 
furthermore, different biological causes or processes that converge on a common final 
pathophysiological pathway might evoke heterogeneity (Ritchie & Touchon, 1992). With 
ever growing evidence of AD heterogeneity, rapidly progressive AD forms (rpAD) might 
very well be one representative of such AD subentities.  
In this book chapter, we review clinical evidence regarding AD heterogeneity in general and 
rapidly progressive AD (rpAD) in particular. Questions arising regard the epidemiological 
evidence for rpAD, its predictability, the biological / pathophysiological basis and the 
impact on therapeutic decision-making (subtype adapted therapy). 
2. Excursus: evidence of AD heterogeneity  
Different disease courses, regarding speed and slope, as well as different phenotypes might 
represent distinct subtypes of AD (Davidson et al., 2010; Geldmacher et al., 2000; Mangone, 
2004). Several attempts have been made to characterize those subtypes, by definition of 
cognitive subgroup patterns, biomarker profiles in the CSF and recently using 
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Age n (patients with rpAD), 
gender 
n, in parenthesis: n 
(subjects with prion 
disease) 




van Everbroeck et al., 
2004 
22mn 71 clinically diagnosed: 45 
(19m, 26f); thereof 30 
confirmed by post 
mortem 
201 (52) 
Collins et al., 2000 n.a. n.a. 3 119 (14) 
Gelpi et al., 2008 n.a. n.a. 6 >900 (206) 
Haïk et al., 2000 n.a. n.a. n.a. 465 
Huang et al.,  2003 n.a. n.a. 1, m 46 (17) 
Jansen et al., 2009 n.a. n.a. 54 280 (146) 
Jayaratnam et al., 2008 4.5mn 74 1, m 1 







Mahmoudi et al., 2010 21mn 74 1, m 1 
Reinwald et al., 2004 40d 69 1, m 1 
Schmidt et al., 2010 26.4mn 73 32 (15m,17f) 32 
Tschampa et al., 2001 24mn 76 19 (4m, 15f) 56 (25) 
Table 1. Neuropathologically confirmed rpAD cases imitating features of prion disease in 
different studies of rapid dementias. (Abbreviations: d=days, f=female, m=male, 
mn=months, n.a.=not available, yrs=years). Table modified from Schmidt et al., 2011. 
2.1 Heterogeneity in AD neuropsychology and imaging 
In a comprehensive overview Cummings presents the knowledge about different 
phenotypes of AD, which also correlate with marked differences in the focal metabolism or 
distinct types of focal atrophy (Cummings, 2000). Firstly, he mentions cognitive 
heterogeneity. Different AD phenotypes may reflect subtypes characterized by marked 
aphasia (Gorno-Tempini et al., 2008; Price et al., 1993), pronounced visoconstructive 
disturbances (Furey-Kurkjian et al., 1996), the variant denominated as "posteriortcortical 
atrophy" (Benson et al, 1988; Tom et al., 1998) and a frontal variant (Foster et al., 1983). For 
all these speculative variants, different metabolism patterns have been demonstrated e.g. by 
means of FDG PET imaging (Foster et al., 1983; Grady et al., 1988; Haxby et al., 1988; Pietrini 
et al., 1996) - as a possible reflection of neurobiological heterogeneity. Boxer and colleagues 
for instance examined AD patients with similar cognitive profiles but marked differences in 
visuoconstructive abilities. More right than left cortical gray matter loss was seen in MRI 
imaging in the visuoconstructively impaired group (esp. right inferior temporal gyrus in 
contrast to the less spatially impaired group). Right inferotemporal atrophy might therefore 
be able to serve as an imaging surrogate marker for visuoconstructive disabilities. Another 
subtype might be AD with salient extrapyramidal signs. Those patients exhibit parkinsonoid 
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features, more severe cognitive decline (Clark et al., 1997) and an increased number of 
neurofibrillary tangles in neuropathology (Liu et al., 1997). Lewy body (LB) pathology is 
common (McKeith et al., 1996) in AD, but the group mentioned here was free from such LB 
features. Behavioral symptoms such as delusion, aggression, depression etc. seem as well to 
be heterogeneous and also show differences especially regarding metabolism (Cummings, 
2000). 
2.2 CSF biomarker evidence of heterogeneity  
Iqbal and colleagues defined disease subtypes based on CSF marker profiles, age at onset, 
clinical profile and disease course (Iqbal et al., 2005). Van der Vlies et al. could also identify 
three AD subtypes using CSF marker profiles (based on Tau, phosphorylated Tau (pTau), 
and Aβ1-42) - corrected for Apoε type, age, gender - showing distinct cognitive profiles on 
neuropsychologic testing (van der Vlies et al., 2009a, 2009b). Especially patients with very 
low Aβ1-42 and high Tau and pTau performed worse on Visual association testing (VAT), 
Trail Making Tests (TMT) and Word Fluency (WF).  
The differences in CSF marker profiles might imply the underlying pathophysiology to 
differ between subtypes. Although this is not proven to date, some findings support this 
hypothesis: Cerebrospinal fluid (CSF) contains a dynamic and complex mixture of proteins, 
which reflects physiological and pathological state of the CNS (Gawinecka & Zerr, 2010; 
Weller, 2001). In AD, levels of both major key players in the disease pathogenesis, namely 
Tau protein and Aβ, are altered in the CSF. These CSF changes are assumed to mirror the 
pathophysiological process in the brain, however, direct comparisons are lacking due to a 
long period between lumbar puncture and CSF tests on the one side and potential autopsy 
and neuropathological workup on the other side.  
2.3 AD heterogeneity in neuropathology  
Also from a pathology point of view evidence has been found to support hypotheses of 
Alzheimer heterogeneity. The basis of neuropathological classification are: Braak's staging, 
describing the distribution of neurofibrillary tangles (NFT), CERAD staging, describing the 
densitiy of neuritic plaques and NIA-RIA criteria, being a synthesis of CERAD and Braak's 
criteria (Murayama & Saito, 2004). Regarding those criteria, neuropathological heterogeneity is 
observed. Ritchie et al. suggest three hypotheses to explain neuropathological heterogeneity in 
AD: 1) subtypes 2) disease stage effects 3) "compensation" (differences in cause / origin and 
progression of AD) (Ritchie & Touchon, 1992).  
Especially heterogeneous cortical atrophy, of which right inferotemporal atrophy 
correlates with visuoconstructive impairment, can be found (Boxer et al., 2003). Recent 
papers reported heterogeneous Aβ deposition patterns in the end stages of the disease 
with variations throughout the neocortex, which cannot be completely explained by a 
regular built up of the pathologic protein during the course of the disease. This implies 
that other biological factors might be involved to build certain phenotypes (Cupidi et al., 
2010). The morphology of Aß deposits is influenced by the cyto- and fibroarchitectonics of 
the brain region in which they are found and by the amount of amyloid present 
(Wisniewski et al., 1989). Factors having an impact thereupon are not fully understood 
(Walker et al., 2008). 
Studies, which focused on neurofibrillar tangles (NFT) in AD revealed significantly different 
NFT densities in various areas of the cerebral cortex without significant differences in the 
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duration of illness, suggesting a possible existence of subgroups. Two distinct subentities in 
AD with different densities of neurofibrillary tangles - but apparently without distinct 
clinical courses could be differentiated (Mizuno et al., 2003). Even in patients with 
presenelin (PSEN) mutations, the neuropathological distribution of different types of 
plaques, intensity of cerebrovascular amyloid and the number of NFT substantially differed 
among individuals, implying that missense mutations in PSEN genes can alter a range of 
key gamma-secretase activities to produce an array of subtly different biochemical, 
neuropathological and clinical manifestations (Maarouf et al., 2008).  
Although the pathological and clinical heterogeneity of AD has been recognized and 
addressed to some extent in the literature, direct studies on clinico-pathological phenotypes 
are sparse. Some authors are arguing against the hypotheses of neuropathological 
heterogeneity. Armstrong et al. for instance examined eighty cases (Armstrong et al., 2000). 
They found that neuropathological differences were rather continuously distributed in 
contrast to the subtype hypotheses. Heterogeneity in plaque and tangle distribution 
correlated more with disease stage (stage hypothesis) rather than being explained by the 
presence of AD subentities. Nonetheless plaque load and distribution was significantly 
influenced by the presence of Apoε type 4 allele. 
3. Definition and epidemiology of rapidly progressive AD 
AD has been a clinical diagnosis since the McKhann Criteria were established in 1984 
(McKhann et al., 1984). Neuroimaging and CSF parameters increasingly came into use 
especially in the first decade of the new millennium leading to newly proposed research 
criteria finally being accepted as a validated instrument to support the diagnostic concept 
(de Meyer et al., 2010; Dubois et al., 2010; Dubois et al., 2007; Gauthier et al., 2008).  
Alois Alzheimer first described the hallmarks of AD with plaques and neurofibrillary 
tangles (NFT) more than a hundred years ago. In synopsis with the clinical presentation, 
neuropathological work-up allows a definite diagnosis. But it has become obvious that AD 
pathology can also exist without significant simultaneous cognitive impairment (Price et al., 
2009). In cases when AD was diagnosed clinically and by post mortem work-up, 
heterogeneity has also been found to exist e.g. in terms of tangle distribution (Mizuno et al., 
2003). Until today it remains subject to controversy how to relate clinical signs and 
symptoms to specific neuropathological lesion patterns or profiles. 
Hypothetically clinically differing disease course could represent distinct subentities of AD 
in terms of heterogeneity. This accounts especially for speed of decline and distinct 
trajectories of that deterioration speed (Davidson et al., 2010; Mangone, 2004). Some 
attempts have been made to characterize these subentities by defining cognitive subgroup 
profiles, CSF biomarker patterns and neuroimaging characteristics (Wilkosz et al., 2010; 
Davidson et al., 2010; Boxer et al., 2003; Cummings, 2000). ( see section 2) 
Disease progression rates have also been used to distinguish AD subtypes. But at the 
moment there is no consensus about the definition of the term “rapidly progressive AD”. 
Moreover the term «rapid» has been used rather arbitrarily. It has been doubtful whether 
“rapid” should be applied to characterize either the rate of cognitive deterioration - and if 
so, on which scales - or the disease duration time (survival time). In addition, the trajectories 
of decline have not been and even are currently not clearly known. They might differ among 
subentities, making a clear definition very difficult. The majority of AD researchers assume 
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a linear slope, but some investigators also suggest trilinear models of decline or even more 
trajectories (Wilkosz et al., 2010; Brooks et al., 1993).  
A variety of definitions has been used in previous studies rather at will. The term “rapid” 
has been applied to describe a survival time below 4 years (Josephs et al., 2009), MMSE 
declines of >5 pts/yr (Doody et al., 2001), >3 pts/yr (Carcaillon et al., 2007), >4pts/0.5yrs 
(Dumont et al., 2005) or >2,56 pts/yr (Buccione et al, 2007) as well as CDR (Clinical 
Dementia Rating Scale) score progression from 1 to 2 or 3 within max. 3 yrs (Bhargava et al., 
2006). Ito et al. observed an average MMSE loss of 5.5 pts/yr in mild to moderate AD in a 
metaanalysis (Ito et al., 2010). Encouraging a discussion and attempt to reach a consensus on 
the term "rapid cognitive decline”, a threshold of 3 or more MMSE pt loss per six months 
has been proposed (Schmidt et al., 2011; Soto et al., 2008). 
Owed to different definitions of "rapid", rpAD seems to constitute approximately 10-30% of 
the AD population. In a longitudinal study with more than 600 AD patients over a two years 
period, Cortes et al. discovered that almost one third of the patients declined faster than 3 
MMSE pts. per year. A tenth deteriorated twice as fast as the whole groups average decline 
of approx. 4.5 pts per year on the MMSE scale (Cortes et al, 2008). Dumont and colleagues, 
in another prospective study, saw one quarter of the cohort decline faster than 4 MMSE 
points within half a year (Dumont et al., 2005). Recently Åsa Wallin and her research group 
were able to show that approximately 8% of their AD study population were characterized 
by a significantly higher mortality and a mean speed of cognitive deterioration of almost 5 
MMSE pts/yr (Wallin et al., 2010). Table 2 gives overview of different studies describing 
rapid progression and its frequency. 
 
study 
definition of "rapid" 
[MMSE decline] 
proportion of study 
population, (n (total)) 
Carcaillon et al., 2007 >3pt/yr 34% (254) 
Ballard et al., 2001 >4pt/yr * 60% (101) 
Cortes et al., 2008 >4.5/yr 11% (686) 
Wallin et al., 2010 >5pt/yr** 8% (151) 
Ballard et al., 2001 >7pt/yr * 32% (101) 
Dumont et al., 2005 >8pt/yr 25% (312) 
Soto et al., 2008a multiple (>3pts/6months) 10%-54% 
Soto et al., 2008b >4pts/first 6 months 14% (565) 
*(«Rapid» is not explicitly defined in this study. The numbers given are mere observations.) 
** Special CSF biomarker cluster 
Table 2. Frequency of rpAD in several clinical studies (longitudinal, cross-sectional, 
retrospective). «Rapid» has been defined by the authors in terms of MMSE decline (column 
1) to specify a «rapid group» out of the AD continuum. (Abbreviations: MMSE=Minimental 
Status Examination, n=number, pts=points, yr=year). Table modified from Schmidt et al., 
2011.  
4. Factors associated with rapid progression 
Much is known about clinical, pathobiochemical and hereditary factors altering the risk of 
developing Alzheimer’s disease, as well as how the risk to advance from Mild Cognitive 
Impairment (MCI) to manifest dementia is modulated by these. But there is a relative lack of 
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knowledge about which signs and symptoms, blood and CSF marker values as well as 
genetic factors actually predict the speed of deterioration in AD.  
4.1 Clinical signs, symptoms and comorbidity as predictors of fast progression 
Several factors such as genetic properties, environmental circumstances, cerebral 
atherosclerosis, cognitive reserve, medical and social support contribute to disease 
progression (Etiene et al., 1998).  
 
sign / comorbidity predictor of 




apathy   Starkstein et al., 2006 (354) 





disease, myocardial infarction 
 
Abellan et al., 
2009 (686) 
Laukka et al., 2010 (138) 
Mielke et al., 2007 (135) 
Roselli et al., 2009 (162) 
Silvestrini et al., 2006 (53) 
chronic systemic 
inflammation  
 Holmes et al., 2010 (300) 
diabetes mellitus Sanz et al., 2009 
(608) 
 Roselli et al., 2009 (162) 
psychotic symptoms   Mangone, 2004 (1000) 
Wilkosz et al., 2009 (201) 
multitude of focal 
neurological signs 
  Josephs et al.,  2009 (1) 
Schmidt et al., 2010 (32) 
Tschampa et al., 2001 (19) 
van Everbroeck et al., 2004 (45) 
high educational level Pavlik et al., 
2009 (rate of 
decline) (478) 
Pavlik et al., 
2009 (survival) 
(478) 
Roselli et al., 2009 (162) 
low educational level   Mangone, 2004 (1000) 
motor signs 
 
 Mangone, 2004 (1000) 
Portet et al., 2009 (388) 
Scarmeas et al., 2005 (533) 
early fast decline   Soto et al., 2008b (565) 
seizures   Volicer et al., 1995 (language function) (27) 
severe cognitive impairment 
at disease onset  
Hui et al., 2003 
(mortality) (354) 
Atchison et al., 2007 (150) 
Ito et al., 2010 (576) 
Marra et al., 2000 (45) 
sex (male)   Roselli et al., 2009 (162) 
Table 3. Clinical signs, symptoms and comorbidity as predictors of disease progression. 
Total number of subjects (AD) in the studies are given in parentheses. Table modified from 
Schmidt et al., 2011. 
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The role of comorbidity is subject to controversy. Diseases of the cardiovascular system and 
diabetes mellitus are commonly accepted as AD disease risk modulators. However, findings 
regarding their impact on disease progression are sometimes contradictory (Table 3) 
(Abellan van Kan et al., 2009; Mielke et al., 2007).  
Fast deterioration also appears to be associated with the occurrence of certain signs and 
symptoms. Among those are especially early signs of the motor system. They are predictors 
of fast decline as well as poor outcome (Mangone, 2004; Portet et al., 2009; Scarmeas et al., 
2005). Another potential indicator / predictor of a rapid disease course might be the 
presence of psychotic symptoms (Wilkosz et al. 2010). Table 3 provides an overview of the 
associations of comorbidity and symptoms with progression of AD.  
Baseline cognitive status and preprogression rates in MMSE decline (estimated MMSE loss 
per time period from onset until diagnosis [pt/yr]) were used as predictive clinical markers 
as well. Another concept of predictive clinical markers has been demonstrated to be useful 
e.g. by Doody et al. in 2001. The baseline cognitive status as well as preprogression rates of 
MMSE decline were able to predict further speed of deterioration. Preprogression rates 
resemble the estimated MMSE loss per time period between the clinical onset to formal 
diagnosis (pts/yr).  
It has been shown by Soto et al., that especially the early loss of 4 MMSE pts within half a 
year was predicting a poorer outcome (Soto et al., 2008b). Additionally, the baseline 
cognitive status is all the more capable of predicting the speed of decline regarding 
functional basic care abilities in AD (Atchison et al., 2007). The baseline level of cognition 
does not necessarily correlate with mortality, nonetheless, the cognitive decline rate features 
a considerable variability in some longitudinal studies (Hui et al., 2003). Recently a 
metaanalysis showed baseline ADAS-Cog values to be covariates of speed of decline (Ito et 
al., 2010). Santillan and coworkers proposed the use of a scale, consisting of the educational 
level, insight assessment, the presence of psychosis, the activities of daily living as well as 
MMSE. Measured at baseline this scale might be capable of estimating the risk of future 
deterioration (Santillan et al., 2003).  
4.2 Imaging and prediction 
An abundance of scientific work has been published regarding imaging in AD. The majority 
deals with either the early diagnosis of AD and differentiation MCI, AD and healthy subject, 
or makes statements about imaging and the risk of developing Alzheimer’s disease, or it 
correlates atrophy rates to stages of AD. Literature about baseline imaging characteristics 
that actually predict the future speed of decline of AD patients (and not the risk of 
progression from MCI to AD) is scarce. Table 4 gives an overview. 
4.3 Predictive biomarkers  
4.3.1 CSF  
CSF markers have become an important part of AD diagnostics. But also as predictors of fast 
decline, they might harbor a certain potential. For instance, rapid cognitive deterioration has 
been demonstrated to be indicated by high total Tau (Tau) protein or hyperphosphorylated 
Tau (pTau) as well as low Aβ1-42 (411pg/ml or less) or a high Tau/Aβ1-42 ratio (0.81 or 
higher) in the cerebrospinal fluid (CSF) respectively (Mungas et al., 2002). Therefore 
attempts have been made to suggest and validate Tau as well as its phosphorylated isoforms 
in particular as prognostic markers. Kester et al. discovered that especially elevated Tau 
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protein without proportionally elevated hyperphosphorylated Tau (pTau) might predict fast 
decline (Kester et al., 2009). Wallin and coworkers recently showed that subjects with very 
high levels of Tau (>1501 (±292) pg/ml) and pTau (>139 (±39) pg/ml) and at the same time 
low levels of Aβ1-42 (< 362 (± 66) pg/ml) deteriorate more rapidly and feature high 
mortality rates (Wallin et al., 2010).  
 
study slower progression 
or no influence 
faster progression 
Adak et al., 2004 (n=225, 
MRI) 
 higher ventricular volume 
Kinkingnehun et al., 2008 
(n=41, MRI, voxel based 
morphometry) 
 extensive cortical atrophy 
 
 
Mungas et al., 2002 (n=120, 
MRI) 
 hippocampal atrophy, cortical 
atrophy 
Ridha et al., 2008 (n=52, 
MRI) 
hippocampal atrophy  




generalized global atrophy and 
early onset and Apoε4 negative 
Swann et al., 1997 
(n[AD]=24, MRI) 
hippocampal atrophy  
Table 4. Imaging and the prediction of AD disease progression. 
It has to be kept in mind that some studies the disease stage might be a confounder: Certain 
CSF marker levels or patterns could as well reflect the disease stage instead of being 
indicative or predictive for the deterioration rate. Data from serial, repeatedly performed 
lumbar punctures and CSF analyses are necessary to control this potential confounding 
factor. Only a small number of studies on this subject have been performed so far. The 
follow up intervals were short. Over a period of 24 months CSF Tau, pTau and Aβ1-42 
appear to be quite constant (Sunderland et al., 1999; Blennow et al., 2007). This hypothesis 
has largely been undergirded by Buchave et al. However, they reported slightly increasing 
Tau values over two years (Buchhave et al., 2009). Contradicting these findings of constancy, 
Stomrud and colleagues demonstrated pTau to increase in a 4 years observation period. 
Furthermore this increment seemed to be associated with cognitive decline (Stomrud et al., 
2010). Regarding Aβ1-42 levels, Huey and colleagues found these to slightly decrease while 
Tau staying stable observed over a period of 4 years (Huey et al., 2006). 
4.3.2 Genetics  
Efforts to investigate genetic predictors in AD have been significantly increased over the 
past years. A number of polymorphisms found seem to have predictive capability in regards 
of speed of decline. Nonetheless, several remain subject to discussion and controversy: 
Among those especially the Apoε gene. This polymorphism is a well established modulator 
of AD disease risk. But its significance as a predictor of progression is not yet as well 
examined. Some researchers claim, that the presence of the ε4 allele predicts fast 
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deterioration especially in mild AD (Cosentino et al., 2008). But in opposition, according to 
van der Vlies, early onset AD is especially rapid, if the subjects are negative for Apoε4 (van 
der Vlies et al., 2009b). A recent study of our research group came to the same result: the ε4 
allele was exceptionally infrequent among rpAD cases (Schmidt et al., 2010). Clues mount 
up that lacking Apoε4 in AD is not only associated with a faster decline but also a more 
atypical course (van der Flier et al., 2011).  
Nevertheless, the research group of Kester and colleagues found no predictive capability of 
Apoε whatsoever (Kester et al., 2009). An overview of different genetic markers associated 
with speed of decline is provided in Table 5.  
 
gene/polymorphism decline 
slow no influence fast 
Apoε4  Kester et al., 2009 (151) Cosentino et al., 2008 
(570) 
no Apoε4   van der Vlies et al., 
2009b (291) 
Schmidt et al., 2010 (32) 
van der Flier et al., 2011 





  Tumini et al., 2007 (321) 
HMGCR (A allele)   Porcellini et al., 2007 
(190+586, 97, 296) 
PSEN1 rs3025780 
(TG genotype) 












(GC + CC genotype) 
ACT-17 (AA genotype) 
ACT promoter 
polymorphism 
(TT genotype) + Apoε4 
  Belbin et al., 2008 
(688+419) 
Kamboh et al., 2006 
(909) 
Licastro et al., 2005 (422) 
IL-1α -889 
(*1/*1 genotype) 
  Murphy et al., 2001 
(114) 
IL-18 -137 (CC 
genotype) 
  Bossu et al.,  2007 (339) 
FAS -1377 
(AG + GG genotype) 
  Chiappelli et al., 2006 
(137+144) 
RAGE G82S 
(GS + SS genotype) 
  Li  et al., 2010 (276+254) 
Table 5. Genetic predictors of cognitive deterioration speed in AD Total number of subjects 
(AD) in the studies are given in parentheses. 
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5. Conclusion  
Until recently, Alzheimer’s disease has been seen as a clinically rather homogeneous 
disease. But during the last decade several studies have differentiated early onset or late 
onset entities as well as fast declining forms. Classification and characterization of these 
disease subentities by means CSF biomarkers and search for indicative patterns as well as 
neuropsychological test batteries has been attempted. However, comprehensive approaches 
to characterize AD subtypes relating clinical characteristics to a neuropathological molecular 
level are lacking (Wilkosz et al., 2010; Doody et al., 2001). Latest pharmacological trials 
implicated that there may be different subtypes within Alzheimer’s disease exhibiting 
different susceptibilities to specific pharmacotherapies (Wallin et al., 2009). Hence, a 
superior characterization of the clinico-pathological heterogeneity and identification of 
predictive factors of disease progression should be able to improve our understanding of 
disease pathogenesis and allow better monitoring in therapeutic settings.   
 
 rpAD classical AD 
survival few years (2-3) 8-10 years 
onset still unclear, around the age of 
73yrs in the study of Schmidt 
et al., 2010 
around age 65yrs (below = 
early onset, above = late 
onset) 
cognitive decline >6 MMSE pts/yr  fast approx. 3-6 MMSE pts/yr 
 slow 
focal neurological signs occurring in early stages, 
multiple (esp. extrapyramidal 
signs) 
occurring in late stages 
CSF biomarkers very high Tau, very high 
pTau, very low A beta 1-42, 
proteins 
high Tau, high pTau, low 
A beta 1-42, proteins 14-3-3 
ApoE4 controversial: its influence on 
decline see Table 4, sometimes 
seen negative in very rapid 
cases (Mann et al., 1989) 
established as a risk factor 
Table 6. Classic AD and rpAD in comparison. Table modified from Schmidt et al., 2011. 
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